Anavex Life Sciences Corp (AVXL)

[falconer66a]

Actually, not a hard sell at all.

Prevention is a much harder sell to many people. It usually requires more effort.

But this won’t be the case with blarcamesine, when incorporated into healthcare insurance.

When blarcamesine has been shown and approved to prevent the onset of various CNS diseases, such as Alzheimer’s and Parkinson’s, healthcare insurance providers will offer two plans; ones without blarcamesine (as presently the case), or others where labeled tablets of blarcamesine are provided for daily or weekly consumption, which lowers the cost of the provided health insurance.

Those electing to remain on traditional health insurance plans will continue to pay ever higher premiums and suffer from CNS diseases as presently the case. Clients who elect to pay lower premiums and take the provided blarcamesine tablets will be ahead three ways: 1) markedly reduced chances of being afflicted with Alzheimer’s or Parkinson’s, 2) will pay significantly lower health insurance premiums, and 3) will benefit from the enhanced sleep blarcamesine produces.

Won’t be a hard sell at all. In time, Alzheimer’s and Parkinson’s clinics will have declining revenues, however.